This week's StoxEurope deep-dive takes UCB SA/NV (UCB, Euronext Brussels) — a Belgian biopharmaceutical company that develops and sells
medicines for people with severe immunological and neurological diseases — through the StoxEurope Valuation Standard.
On 22 October 2026 UCB raised its 2026 guidance for the third time this
year: revenue growth "in the low twenties" and adjusted EBITDA growth
"in the low- to mid-forties", both at constant exchange rates. The share
closed at €213,00 on 21 October and at €259,10 on 22 October. UCB guides
one year at a time, so our deep-dive asks one question: what is the business worth if the 2026 margin holds?
The StoxEurope estimate
The StoxEurope estimate is €232,56 per share on 28 October 2026. It
comes from the primary model — the discounted cash flow of the whole
business.
Across the three modelled scenarios the primary model gives €181,12 to
€297,58: the guidance at its low end, then the margin back to 2025; the
guidance, then held; or the guidance at constant exchange rates, on
UCB's own base. Those are three modelled scenarios, not a statistical
confidence interval.
The share price on 28 October 2026 was €270,50. The article also reads
the same forecast under two other conventions, free cash flow to equity
and the payout model; they are never averaged in.
Three assumptions behind it
2026 sales grow 16,5 %: UCB's "low twenties" less the currency gap of the first half. The operating margin is then held at 28,99 % in every forecast year. Neurona, Candid and IMIDomics are counted at the €2.227 m UCB paid.
The discount rate is 7,24 %, with a beta of 0,77, halfway between UCB's own measured beta of 0,46 and the industry figure of 1,08. On the industry figure alone the estimate would be €43,77 a share lower; on UCB's own beta alone, €68,06 higher.
Each test changes the condition it names, all other inputs stay at base. We have not tested combinations of smaller changes. This is not a statement of what investors believe.
The uncertainty that matters most
Our base holds an operating margin of 28,99 % from 2026. UCB guides 2026
only; its 2026 results on 25 February 2027 are the first full-year test.
About three quarters of the value comes from after 2030.
The full workings
Read the full valuation — every assumption, every model, the full workings: https://stoxeurope.com/valuation/ucb-october-2026/
Disclosures
Position disclosure: A long position is held in UCB SA/NV, through shares. Ledger-verified as at 30 October 2026. This valuation is general, impersonal research—not personalised investment advice or an offer to trade. It reflects stated assumptions and information available at publication; estimates are uncertain, may change and are not guarantees. To the fullest extent permitted by law, StoxEurope accepts no liability for reliance on this publication.
Readers should conduct their own research and review the disclosed
methodology, risks and conflicts.